Indoco Remedies Limited (NSE:INDOCO)
India · Delayed Price · Currency is INR 219.90
+3.21 (1.48%)
Jul 31, 2026, 3:30 PM IST
Indoco Remedies Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 18,283 | 17,929 | 16,649 | 18,173 | 16,686 | 15,408 |
Other Revenue | 448.5 | 523.8 | - | - | - | - |
| 18,732 | 18,453 | 16,649 | 18,173 | 16,686 | 15,408 | |
Revenue Growth | 12.08% | 10.84% | -8.38% | 8.91% | 8.30% | 24.10% |
Cost of Revenue | 5,648 | 5,417 | 5,556 | 6,204 | 5,661 | 4,946 |
Gross Profit | 13,083 | 13,036 | 11,094 | 11,969 | 11,025 | 10,461 |
Selling, General & Admin | 4,201 | 4,257 | 5,259 | 4,618 | 3,941 | 3,421 |
Research & Development | 764.2 | 795.4 | 760.12 | 971.57 | 809.7 | 746.42 |
Other Operating Expenses | 6,465 | 6,566 | 4,075 | 3,925 | 3,399 | 3,001 |
Operating Expenses | 12,743 | 12,882 | 11,232 | 10,435 | 8,856 | 7,954 |
Operating Income | 340.1 | 153.5 | -138.5 | 1,534 | 2,169 | 2,507 |
Interest Expense | -1,244 | -1,223 | -620.29 | -349.3 | -237.5 | -164.58 |
Interest & Investment Income | - | - | 8.46 | 39.59 | 5.85 | 4.77 |
Currency Exchange Gain (Loss) | - | - | -22.18 | 9.82 | 2.43 | 32.9 |
Other Non Operating Income (Expenses) | 38.8 | 33.3 | 17.3 | 10.26 | 0.33 | 8.57 |
EBT Excluding Unusual Items | -865.3 | -1,036 | -755.22 | 1,244 | 1,941 | 2,388 |
Gain (Loss) on Sale of Investments | - | - | 6.59 | 2.44 | - | - |
Gain (Loss) on Sale of Assets | - | - | -5.02 | -3.78 | -12.62 | -5.11 |
Asset Writedown | - | - | - | - | - | -17.47 |
Other Unusual Items | 944 | -29.4 | 9.94 | 115.28 | - | - |
Pretax Income | 78.7 | -1,065 | -743.71 | 1,358 | 1,928 | 2,366 |
Income Tax Expense | 47.8 | -78.1 | 35.81 | 387.95 | 505.41 | 817.72 |
Earnings From Continuing Operations | 30.9 | -987 | -779.51 | 970.04 | 1,423 | 1,548 |
Minority Interest in Earnings | 25.4 | 35.5 | 42.14 | 14.56 | - | - |
Net Income | 56.3 | -951.5 | -737.37 | 984.6 | 1,423 | 1,548 |
Net Income to Common | 56.3 | -951.5 | -737.37 | 984.6 | 1,423 | 1,548 |
Net Income Growth | - | - | - | -30.78% | -8.11% | 66.37% |
Shares Outstanding (Basic) | 89 | 89 | 92 | 92 | 92 | 92 |
Shares Outstanding (Diluted) | 89 | 89 | 92 | 92 | 92 | 92 |
Shares Change | 15.76% | -3.55% | -0.07% | 0.01% | 0.11% | - |
EPS (Basic) | 0.63 | -10.70 | -8.00 | 10.68 | 15.44 | 16.80 |
EPS (Diluted) | 0.63 | -10.70 | -8.00 | 10.67 | 15.42 | 16.80 |
EPS Growth | - | - | - | -30.79% | -8.21% | 66.37% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 447 | -2,612 | -2,706 | -284.23 | 485.04 |
Free Cash Flow Per Share | - | 5.03 | -28.33 | -29.33 | -3.08 | 5.26 |
Dividend Per Share | - | 0.200 | 0.200 | 1.500 | 2.250 | 1.500 |
Dividend Growth | - | 0% | -86.67% | -33.33% | 50.00% | 0% |
Gross Margin | 69.85% | 70.64% | 66.63% | 65.86% | 66.07% | 67.90% |
Operating Margin | 1.82% | 0.83% | -0.83% | 8.44% | 13.00% | 16.27% |
Profit Margin | 0.30% | -5.16% | -4.43% | 5.42% | 8.53% | 10.05% |
Free Cash Flow Margin | - | 2.42% | -15.69% | -14.89% | -1.70% | 3.15% |
EBITDA | 1,673 | 1,418 | 852.29 | 2,124 | 2,719 | 2,999 |
EBITDA Margin | 8.93% | 7.68% | 5.12% | 11.68% | 16.30% | 19.46% |
D&A For EBITDA | 1,333 | 1,265 | 990.79 | 589.92 | 549.88 | 492.24 |
EBIT | 340.1 | 153.5 | -138.5 | 1,534 | 2,169 | 2,507 |
EBIT Margin | 1.82% | 0.83% | -0.83% | 8.44% | 13.00% | 16.27% |
Effective Tax Rate | 60.74% | - | - | 28.57% | 26.21% | 34.56% |
Revenue as Reported | 18,770 | 18,487 | 16,704 | 18,271 | 16,709 | 15,431 |
Advertising Expenses | - | - | 1,318 | 999.09 | 715.66 | 458.47 |